Northwire Canada EditionFriday, July 17, 2026

Sign in Subscribe

SFR 0.370 +68.2% OMM 0.050 +0.0% EMO 0.340 −1.4% GGA 5.50 +3.8% MDM 0.060 +0.0% WGX 4.33 −2.3% FL 0.410 +0.0% SSRM 36.30 −0.2% CD 0.240 +4.3% GEN 0.065 −7.1% ALS 56.17 −2.2% LIFT 3.11 −1.3% NTR 94.34 +0.1% ICON 0.045 +0.0% LMG 0.450 +0.0% NZP 0.045 −10.0% SFR 0.370 +68.2% OMM 0.050 +0.0% EMO 0.340 −1.4% GGA 5.50 +3.8% MDM 0.060 +0.0% WGX 4.33 −2.3% FL 0.410 +0.0% SSRM 36.30 −0.2% CD 0.240 +4.3% GEN 0.065 −7.1% ALS 56.17 −2.2% LIFT 3.11 −1.3% NTR 94.34 +0.1% ICON 0.045 +0.0% LMG 0.450 +0.0% NZP 0.045 −10.0%

Earnings

BioSyent to release Q3 results Nov. 20

By The Northwire Desk — AI Analysis Nov 13, 2025 · 20:43 RX · 10.9 BioSyent Inc

RX · Price

Executive Summary

BioSyent Inc. will announce its Q3 2025 and year‑to‑date 2025 financial results on Thursday, November 20, 2025, after market hours.
The earnings presentation, prepared by President & CEO Rene Goehrum, will be posted on the company’s website concurrent with the release.

Key Details

Announcement date: Thursday, Nov 20, 2025 (after‑hours).
Coverage period: Three months and nine months ended Sept. 30, 2025.
Presentation author: Rene Goehrum, President & Chief Executive Officer.
Presentation availability: Posted on BioSyent’s website on the release date.

Notable Quotes

(No quotes were provided in the release.)

Read the original news release →

More from BioSyent Inc

May 19, 2026 · 09:52

BioSyent enters endocrinology with sole-source liquid levothyroxine — a niche launch, but the upside hinges on Tibella/FeraMAX still doing the heavy lifting.

Regulatory May 14, 2026 · 18:00

BioSyent’s Q1 Shows Oral Science Deal Paying Off, but Pharma Core Holds Steady

Earnings Mar 19, 2026 · 17:30

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025

Earnings Mar 12, 2026 · 17:30

BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026

Earnings Mar 02, 2026 · 21:07

BioSyent closes Oral Science acquisition, grants RSUs

M&A / Property Mar 02, 2026 · 08:30

BioSyent Announces Closing of the Acquisition of Oral Science Inc.